A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Myeong Jun | - |
dc.contributor.author | Bae, Si Hyun | - |
dc.contributor.author | Chun, Ho Jong | - |
dc.contributor.author | Choi, Jong Young | - |
dc.contributor.author | Yoon, Seung Kew | - |
dc.contributor.author | Park, Jun Young | - |
dc.contributor.author | Han, Kwang Hyub | - |
dc.contributor.author | Kim, Young Seok | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Chung, Woo Jin | - |
dc.contributor.author | Hwang, Jae Seok | - |
dc.contributor.author | Cho, Sung-Bum | - |
dc.contributor.author | Eun, Jong Ryul | - |
dc.date.accessioned | 2021-09-04T17:34:44Z | - |
dc.date.available | 2021-09-04T17:34:44Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-04 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/93915 | - |
dc.description.abstract | This multicenter, randomized, open-labeled, clinical trial evaluated the efficacy and safety of cisplatin/5-fluorouracil (5-FU) hepatic arterial infusion chemotherapy (CF-HAIC) versus adriamycin adding to CF-HAIC (ACF-HAIC) in advanced HCC patients. Fifty-six patients with advanced HCC were randomized to two treatment groups: (1) CF-HAIC group [n = 29, 5-FU, 500 mg/m(2) on days 1-3, and cisplatin, 60 mg/m(2) on day 2] and (2) ACF-HAIC group [n = 27, adriamycin, 50 mg/m(2) on day 1, 5-FU, 500 mg/m(2) on days 1-3, and cisplatin, 60 mg/m(2) on day 2] every 4 weeks via an implantable port system. Primary efficacy endpoint was overall survival (OS). Treatment response and time to progression were secondary endpoints. Treatment response rates did not differ significantly between the two treatment groups. Time to progression (5.4 vs. 5.8 months, P = 0.863) and OS (11.1 vs. 8.8 months, P = 0.448) were not significantly different. When the factors affecting patient OS were analyzed, disease control rate [P < 0.001, HR 6.437 (95 % CI 2.580-16.064)] was independently associated with OS. Age (a parts per thousand yen60 years) and serum AFP level (a parts per thousand yen200 ng/dL) also were significant factors for OS [P = 0.007, HR 4.945 (95 % CI 1.543-15.850), P = 0.048, HR 2.677 (95 % CI 1.010-7.095), respectively]. Grade 4 treatment-related toxicity and mortality was not observed in both groups. Although both HAIC regimens are safe and effective in patients with advanced HCC, HAIC adding adriamycin did not show delayed tumor progression and survival benefit compared to CF-HAIC in advanced HCC. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | VEIN TUMOR THROMBOSIS | - |
dc.subject | DRUG-DELIVERY SYSTEM | - |
dc.subject | LOW-DOSE CISPLATIN | - |
dc.subject | PORTAL-VEIN | - |
dc.subject | 5-FLUOROURACIL | - |
dc.subject | CLASSIFICATION | - |
dc.subject | COMBINATION | - |
dc.subject | EPIRUBICIN | - |
dc.subject | SURVIVAL | - |
dc.subject | CANCER | - |
dc.title | A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yim, Hyung Joon | - |
dc.contributor.affiliatedAuthor | Um, Soon Ho | - |
dc.identifier.doi | 10.1007/s00280-015-2692-0 | - |
dc.identifier.scopusid | 2-s2.0-84925462711 | - |
dc.identifier.wosid | 000351549100009 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.75, no.4, pp.739 - 746 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.title | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.volume | 75 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 739 | - |
dc.citation.endPage | 746 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | VEIN TUMOR THROMBOSIS | - |
dc.subject.keywordPlus | DRUG-DELIVERY SYSTEM | - |
dc.subject.keywordPlus | LOW-DOSE CISPLATIN | - |
dc.subject.keywordPlus | PORTAL-VEIN | - |
dc.subject.keywordPlus | 5-FLUOROURACIL | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | EPIRUBICIN | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Hepatic arterial infusion chemotherapy | - |
dc.subject.keywordAuthor | 5-Fluorouracil | - |
dc.subject.keywordAuthor | Cisplatin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.